Valuation: Gilead Sciences, Inc.

Capitalization 15TCr 13TCr 12TCr 12TCr 22TCr 14,06100Cr 23TCr 1,43100Cr 56TCr 6,70700Cr 58TCr 57TCr 24,49100Cr P/E ratio 2025 *
18.6x
P/E ratio 2026 * 16.8x
Enterprise value 17TCr 14TCr 13TCr 13TCr 23TCr 15,22900Cr 25TCr 1,54900Cr 61TCr 7,26400Cr 63TCr 62TCr 26,52500Cr EV / Sales 2025 *
5.75x
EV / Sales 2026 * 5.33x
Free-Float
99.9%
Yield 2025 *
2.66%
Yield 2026 * 2.79%
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.42%
1 week+3.15%
Current month+1.77%
1 month+5.16%
3 months+5.99%
6 months+13.71%
Current year+1.77%
More quotes
1 week 119.63
Extreme 119.63
125.12
1 month 116.88
Extreme 116.88
127.41
Current year 116.88
Extreme 116.88
125.12
1 year 91.84
Extreme 91.84
128.7
3 years 62.07
Extreme 62.07
128.7
5 years 57.16
Extreme 57.165
128.7
10 years 56.56
Extreme 56.56
128.7
More quotes
Manager TitleAgeSince
Chief Executive Officer 60 01/03/2019
Director of Finance/CFO 56 01/11/2019
Chief Tech/Sci/R&D Officer 64 02/01/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+3.01%+3.15%+36.29%+44.79% 15TCr
+0.53%-2.37%+37.06%+187.15% 93TCr
-0.41%+6.98%+47.97%+26.08% 53TCr
-0.31%-2.60%+23.40%+39.55% 38TCr
+0.93%+2.38%+29.90%+18.43% 37TCr
+0.19%-1.15%+29.58%+20.35% 29TCr
-1.93%-1.54%+8.07%-3.05% 27TCr
+0.98%+1.37%+27.61%+34.08% 28TCr
+6.49%+1.95%-35.37%-18.36% 27TCr
+0.12%+1.32%+22.63%+21.59% 18TCr
Average +0.70%+0.95%+22.72%+37.06% 36.46TCr
Weighted average by Cap. +0.59%+0.62%+26.96%+63.07%
See all sector performances

Financials

2025 *2026 *
Net sales 2.92TCr 2.52TCr 2.34TCr 2.18TCr 4.06TCr 2,65100Cr 4.37TCr 27TCr 11TCr 1,26400Cr 11TCr 11TCr 4,61700Cr 3.02TCr 2.6TCr 2.42TCr 2.25TCr 4.2TCr 2,73800Cr 4.52TCr 28TCr 11TCr 1,30600Cr 11TCr 11TCr 4,76800Cr
Net income 804.67Cr 693.71Cr 645.79Cr 601.2Cr 1.12TCr 73TCr 1.2TCr 7.43TCr 2.93TCr 35TCr 3.02TCr 2.96TCr 1,27200Cr 889.91Cr 767.19Cr 714.2Cr 664.89Cr 1.24TCr 81TCr 1.33TCr 8.22TCr 3.24TCr 39TCr 3.34TCr 3.27TCr 1,40600Cr
Net Debt 1.29TCr 1.11TCr 1.03TCr 961.49Cr 1.79TCr 1,16800Cr 1.93TCr 12TCr 4.68TCr 56TCr 4.83TCr 4.73TCr 2,03400Cr 575.5Cr 496.14Cr 461.86Cr 429.98Cr 800.57Cr 52TCr 861.34Cr 5.31TCr 2.09TCr 25TCr 2.16TCr 2.11TCr 91TCr
More financial data * Estimated data
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (99.5%): for the treatment of HIV (68.5% of net sales), oncology diseases (11.5%), hepatitis B virus (10.6%), Ebola virus (6.3%) and other (3.1%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (0.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (71.6%), Europe (16.1%) and other (12.3%).
Employees
17,600
More about the company
Date Price Change Volume
16/26/16 124.91 $ +3.01% 1,06,39,074
15/26/15 121.26 $ -2.26% 66,59,785
14/26/14 124.07 $ +1.90% 46,59,420
13/26/13 121.76 $ -0.69% 58,03,884
12/26/12 122.60 $ +1.24% 73,97,037

Delayed Quote Nasdaq, January 17, 2026 at 02:30 am IST

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AAA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
124.91USD
Average target price
134.19USD
Spread / Average Target
+7.43%
Consensus

Quarterly revenue - Rate of surprise